Compare Adaptive Biotechnologies Corp (ADPT) vs Main Street Capital Corporation (MAIN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Main Street Capital Corporation — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Main Street Capital Corporation trades at $51.17 (market cap $4.87B). The key difference: Main Street Capital Corporation is the larger of the two by market cap, and Main Street Capital Corporation pays a 8.36% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | MAIN | |
|---|---|---|
Market Cap | $3.33B | $4.87B |
Sector | Health | Financials |
52-Week High | $22.37 | $67.54 |
52-Week Low | $10.24 | $49.63 |
Enterprise Value | $3.19B | — |
Dividend Yield | — | 8.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Main Street Capital (MAIN) trades at $52.41, up 0.87% on the day, with a bullish technical signal and strong support near $52. The company reported a net income margin of 81.08% for 2025, though revenue declined slightly to $592 million. Recent corporate actions include a credit facility amendment extending maturity to 2031 and consistent dividend payments, highlighting its income-focused appeal.
Outlook remains mixed; the stock offers a high yield and stable dividends, but earnings misses and a high RSI suggest near-term caution. Analyst consensus is a Hold with a $57.75 price target, indicating modest upside potential amid execution risks and economic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →
